MA26829A1 - Derives de purines - Google Patents

Derives de purines

Info

Publication number
MA26829A1
MA26829A1 MA26591A MA26591A MA26829A1 MA 26829 A1 MA26829 A1 MA 26829A1 MA 26591 A MA26591 A MA 26591A MA 26591 A MA26591 A MA 26591A MA 26829 A1 MA26829 A1 MA 26829A1
Authority
MA
Morocco
Prior art keywords
purine derivatives
purine
derivatives
Prior art date
Application number
MA26591A
Other languages
English (en)
Inventor
Marina Monaghan Sandra
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA26829A1 publication Critical patent/MA26829A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
MA26591A 1999-10-14 2002-04-09 Derives de purines MA26829A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9924361.0A GB9924361D0 (en) 1999-10-14 1999-10-14 Purine derivatives

Publications (1)

Publication Number Publication Date
MA26829A1 true MA26829A1 (fr) 2004-12-20

Family

ID=10862758

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26591A MA26829A1 (fr) 1999-10-14 2002-04-09 Derives de purines

Country Status (43)

Country Link
US (1) US6448236B1 (fr)
EP (1) EP1220862B1 (fr)
JP (1) JP3994008B2 (fr)
KR (1) KR20030022758A (fr)
CN (1) CN1166678C (fr)
AP (1) AP2002002480A0 (fr)
AR (1) AR026052A1 (fr)
AT (1) ATE321065T1 (fr)
AU (1) AU771531B2 (fr)
BG (1) BG106567A (fr)
BR (1) BR0014760A (fr)
CA (1) CA2387533C (fr)
CO (1) CO5261621A1 (fr)
CR (1) CR6607A (fr)
CZ (1) CZ20021179A3 (fr)
DE (1) DE60026861T2 (fr)
EA (1) EA004985B1 (fr)
EC (1) ECSP003713A (fr)
EE (1) EE200200194A (fr)
ES (1) ES2257317T3 (fr)
GB (1) GB9924361D0 (fr)
GE (1) GEP20043324B (fr)
GT (2) GT200000170A (fr)
HK (1) HK1047942B (fr)
HR (1) HRP20020325A2 (fr)
HU (1) HUP0203485A3 (fr)
IL (1) IL148331A0 (fr)
IS (1) IS6287A (fr)
MA (1) MA26829A1 (fr)
MX (1) MXPA02003750A (fr)
MY (1) MY141512A (fr)
NO (1) NO20021751L (fr)
NZ (1) NZ517294A (fr)
OA (1) OA12060A (fr)
PA (1) PA8503601A1 (fr)
PE (1) PE20010753A1 (fr)
PL (1) PL354880A1 (fr)
SK (1) SK4742002A3 (fr)
SV (1) SV2002000199A (fr)
TN (1) TNSN00203A1 (fr)
TR (1) TR200201001T2 (fr)
WO (1) WO2001027131A1 (fr)
ZA (1) ZA200202725B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0015727D0 (en) * 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US20050033044A1 (en) * 2003-05-19 2005-02-10 Bristol-Myers Squibb Pharma Company Methods for preparing 2-alkynyladenosine derivatives
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
BRPI0509258A8 (pt) 2004-03-26 2019-01-22 Astrazeneca Ab composto de 8-oxoadenina 9-substituída
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE602005020286D1 (de) 2004-05-26 2010-05-12 Inotek Pharmaceuticals Corp Purinderivate als adenosin a 1 rezeptoragonisten und anwendungsverfahren dafür
JP5011112B2 (ja) * 2004-09-20 2012-08-29 イノテック ファーマシューティカルズ コーポレイション プリン誘導体を含有する炎症性疾患の治療用医薬
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
AU2006320578B2 (en) * 2005-11-30 2013-01-31 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
SI2013211T1 (sl) * 2006-04-21 2012-07-31 Novartis Ag Purinski derivati za uporabo kot agonisti receptorja adenozina A A
JP2009542645A (ja) 2006-07-05 2009-12-03 アストラゼネカ・アクチエボラーグ Ｔｌｒ７のモジュレーターとして作用する８−オキソアデニン誘導体
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
EP2089393A1 (fr) 2006-10-30 2009-08-19 Novartis AG Composés hétérocycliques en tant qu'agents anti-inflammatoires
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
EP2118106A1 (fr) * 2007-03-02 2009-11-18 Glaxo Group Limited Purines comme inhibiteurs de la cystéine protéase
ATE530549T1 (de) * 2007-03-19 2011-11-15 Astrazeneca Ab 9-substituierte 8-oxoadeninverbindungen als modulatoren des toll-like-receptor (tlr7)
EP2132209B8 (fr) * 2007-03-19 2014-04-16 AstraZeneca AB Composés 8-oxo-adenine 9 substitué comme modulateurs du récepteur de type toll (tlr7)
PE20081887A1 (es) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
JPWO2008114819A1 (ja) 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
JP5400763B2 (ja) * 2007-05-08 2014-01-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
WO2009091031A1 (fr) * 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co., Ltd. Procédé de production d'un composé d'adénine
KR20100125245A (ko) 2008-01-17 2010-11-30 다이닛본 스미토모 세이야꾸 가부시끼가이샤 아데닌 화합물의 제조 방법
JP2012516345A (ja) 2009-01-29 2012-07-19 ノバルティス アーゲー 星細胞腫治療用置換ベンゾイミダゾール
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
ES2709108T3 (es) 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
AU2010284972A1 (en) 2009-08-20 2012-03-08 Novartis Ag Heterocyclic oxime compounds
JP2013512859A (ja) * 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
SI2523669T1 (sl) 2010-01-11 2017-05-31 Inotek Pharmaceuticals Corporation Kombinacija, komplet in metoda za zmanjšanje intraokularnega tlaka
BR112012023749A2 (pt) 2010-03-26 2016-08-23 Inotek Pharmaceuticals Corp método para reduzir a pressão intraocular em humanos utilizando n6-ciclopentiladenosina (cpa), derivados de cpa ou pró-fármacos desses
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
EP2651937B8 (fr) 2010-12-16 2016-07-13 Sumitomo Dainippon Pharma Co., Ltd. Dérivé imidazo[4,5-c]quinolin-1-yle utile en thérapie
JP5978226B2 (ja) 2010-12-17 2016-08-24 大日本住友製薬株式会社 プリン誘導体
EP2673277A1 (fr) 2011-02-10 2013-12-18 Novartis AG Composés de [1, 2, 4]triazolo [4, 3 -b]pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
WO2012116217A1 (fr) 2011-02-25 2012-08-30 Irm Llc Composés et compositions en tant qu'inhibiteurs de trk
BR112014006223A8 (pt) 2011-09-15 2018-01-09 Novartis Ag 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
KR20140128974A (ko) 2012-01-26 2014-11-06 이노텍 파마슈티컬스 코포레이션 ((2r,3s,4r,5r)-5-(6-(시클로펜틸아미노)-9h-퓨린-9-일)-3,4-디히드록시테트라히드로푸란-2-일) 메틸 니트레이트의 무수 다형체들 및 이들의 제조 방법들
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
EP2968340A4 (fr) 2013-03-15 2016-08-10 Intellikine Llc Combinaison d'inhibiteurs de kinase et ses utilisations
SG11201506882YA (en) 2013-03-15 2015-09-29 Inotek Pharmaceuticals Corp Ophthalmic formulations
WO2015084804A1 (fr) 2013-12-03 2015-06-11 Novartis Ag Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
MX2017001461A (es) 2014-07-31 2017-05-11 Novartis Ag Terapia de combinacion.
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5536419A (en) * 1978-09-08 1980-03-14 Yamasa Shoyu Co Ltd 2-substituted adenosine derivative and its preparation
WO1988003147A1 (fr) * 1986-10-31 1988-05-05 Warner-Lambert Company Adenosines a substitution n6 selectionees ayant une activite de liaison a2 selective
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DE69932173T2 (de) * 1998-10-16 2007-06-06 Pfizer Inc. Adeninderivate
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives

Also Published As

Publication number Publication date
KR20030022758A (ko) 2003-03-17
EE200200194A (et) 2003-06-16
NO20021751L (no) 2002-06-13
HK1047942A1 (en) 2003-03-14
NO20021751D0 (no) 2002-04-12
BR0014760A (pt) 2002-07-02
EP1220862A1 (fr) 2002-07-10
GEP20043324B (en) 2004-04-13
CR6607A (es) 2003-11-25
DE60026861T2 (de) 2006-09-21
ECSP003713A (es) 2002-05-23
MXPA02003750A (es) 2003-10-14
PE20010753A1 (es) 2001-07-17
ES2257317T3 (es) 2006-08-01
TNSN00203A1 (fr) 2002-05-30
CN1166678C (zh) 2004-09-15
US6448236B1 (en) 2002-09-10
BG106567A (en) 2002-12-29
MY141512A (en) 2010-05-14
GB9924361D0 (en) 1999-12-15
TR200201001T2 (tr) 2002-09-23
HUP0203485A2 (hu) 2003-03-28
ZA200202725B (en) 2003-04-08
CN1378551A (zh) 2002-11-06
ATE321065T1 (de) 2006-04-15
HK1047942B (zh) 2005-04-01
IL148331A0 (en) 2002-09-12
EA200200360A1 (ru) 2002-10-31
GT200000173A (es) 2002-04-05
EA004985B1 (ru) 2004-10-28
OA12060A (en) 2006-05-03
HRP20020325A2 (en) 2004-04-30
AR026052A1 (es) 2002-12-26
IS6287A (is) 2002-02-26
CA2387533A1 (fr) 2001-04-19
HUP0203485A3 (en) 2005-02-28
GT200000170A (es) 2002-04-03
SV2002000199A (es) 2002-02-05
AU7441200A (en) 2001-04-23
CZ20021179A3 (cs) 2003-04-16
PL354880A1 (en) 2004-03-22
AU771531B2 (en) 2004-03-25
SK4742002A3 (en) 2003-05-02
PA8503601A1 (es) 2002-02-21
JP2003511460A (ja) 2003-03-25
EP1220862B1 (fr) 2006-03-22
WO2001027131A1 (fr) 2001-04-19
CO5261621A1 (es) 2003-03-31
AP2002002480A0 (en) 2002-06-30
NZ517294A (en) 2004-03-26
JP3994008B2 (ja) 2007-10-17
DE60026861D1 (de) 2006-05-11
CA2387533C (fr) 2007-03-13

Similar Documents

Publication Publication Date Title
MA26829A1 (fr) Derives de purines
MA26828A1 (fr) Derives de purines
MA26799A1 (fr) Derives de purine
MA26918A1 (fr) Derives de purine
ATE231874T1 (de) Antivirale purin-derivate
ATE325807T1 (de) Purinderivate
NO20010743D0 (no) Antivirale indoloksoacetyl-piperazin-derivater
MA26967A1 (fr) Derives de pyrimidine
ES1050663Y (es) Batidor de purines perfeccionado